Jody Chu on Muck Rack

Jody Chu

As seen in: Drug Science
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jody

Contact Jody, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Germany Pioneers Compassionate Psilocybin Access for Treatment-Resistant Depression in EU First

|
By Jody Chu, James Bunn
| Drug Science
By Jody Chu and James Bunn Germany has recently taken a landmark step by introducing compassionate access to psilocybin for patients with treatment-resistant depression (TRD), marking the first such programme in the European Union. This initiative allows eligible patients to receive psilocybin treatment outside of clinical trials under a legal framework designed for compassionate use.
Open in Who Shared Issue with article?

UK Government supports ACMD plan to enable research with schedule 1 medicines such as psilocybin and MDMA

|
By James Bunn, Jo Neill, Jody Chu
| Drug Science
By Jody Chu, James Bunn and Prof Jo Neill Despite the resurgence of research into the clinical efficacy and mechanism of action of psychedelic drugs such as such as psilocybin, LSD, DMT, and MDMA they are currently in Schedule 1 of the Misuse of Drugs regulations 2001. This means that researchers must apply for a controlled drugs licence from the Home Office to possess, supply, or administer these substances, even when ethical and regulatory approvals are already in place.
Open in Who Shared Issue with article?
See all 2 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified